MAFLD Screening in Australia: A Practical Clinical Guide

1. Why MAFLD Screening Matters in Primary Care

Metabolic dysfunction-associated fatty liver disease (MAFLD, also called MASLD in the 2023 international nomenclature) is now the most common chronic liver condition in Australia. Population estimates from AusDiab and downstream modelling suggest approximately 37% of Australian adults have MAFLD — more than 5 million people. Of those, a clinically significant minority will progress to advanced fibrosis, cirrhosis, or hepatocellular carcinoma if undetected.

The challenge for primary care is that MAFLD is silent. ALT can be normal even in advanced fibrosis. Patients present with type 2 diabetes, obesity, cardiovascular risk, or metabolic syndrome — the liver disease sits in the background, often unmeasured, until late-stage complications force attention.

The opportunity is that MAFLD is now well-defined, well-staged, and well-managed when caught early. GESA's 2023 MAFLD clinical care pathway, EASL 2023 guidelines, and the international Delphi consensus on nomenclature have together produced a coherent framework that any well-run general practice can implement.

2. Who to Screen — Risk-Based Triage

Population screening for MAFLD is not currently recommended. Risk-based screening of higher-prevalence groups is. The patient cohorts where MAFLD prevalence is materially elevated and screening yield justifies the workup:

• Type 2 diabetes: MAFLD prevalence in T2DM populations is 50–75%. Significant fibrosis is present in 15–20% of these patients.
• Obesity (BMI ≥30): MAFLD prevalence 50–80%; the proportion with significant fibrosis correlates with BMI severity.
• Metabolic syndrome: any patient meeting metabolic syndrome criteria has elevated MAFLD risk regardless of BMI.
• Elevated waist circumference: >94cm men, >80cm women (Asian-specific thresholds where relevant).
• Persistent ALT elevation: ALT above the upper limit of normal on two occasions ≥3 months apart, regardless of other risk factors.
• Incidental fatty liver on imaging: ultrasound steatosis findings — even when reported as "mild" — warrant FIB-4 assessment.

3. The FIB-4 First-Line Filter

FIB-4 is the recommended first-line tool for risk stratification in Australian primary care. It uses four routine values — age, AST, ALT, and platelet count — and produces a probability score for advanced fibrosis. It costs nothing additional when these labs are already being ordered.

The FIB-4 thresholds:

• FIB-4 <1.3 (or <2.0 in patients ≥65 years): low risk. Negative predictive value 95–97% for advanced fibrosis. No elastography required. Repeat FIB-4 in 1–3 years based on overall risk profile.
• FIB-4 1.3–2.67: indeterminate zone. Elastography is recommended as the next step to clarify fibrosis status.
• FIB-4 >2.67: high risk for advanced fibrosis. Specialist hepatology referral is appropriate; elastography supports the referral but does not replace it.

The indeterminate zone is the most clinically important. In real-world Australian primary care cohorts, around 30–40% of screened MAFLD patients fall into this zone. Without a clear next step, these patients tend to enter an indefinite "watch and wait" loop. The whole point of having an elastography pathway is to convert indeterminate results into actionable answers.

4. The Elastography Step

For patients with indeterminate FIB-4, transient elastography (VCTE) or guided 2D shear-wave elastography (2D-SWE) provides an objective liver stiffness measurement in kPa. The general MAFLD thresholds:

• <8 kPa: low-risk fibrosis. Continue routine metabolic management; repeat elastography in 2–3 years.
• 8–12 kPa: significant fibrosis. Specialist input is recommended; repeat elastography annually while on treatment.
• >12 kPa: advanced fibrosis or cirrhosis likely. Specialist referral; consider HCC surveillance imaging.

Two practical issues affect Australian primary care: access and reliability. Access has historically been variable — concentrated in hospitals and some imaging centres. Reliability matters because elastography can fail in higher-BMI patients (a significant proportion of the MAFLD cohort). Guided systems with real-time B-mode imaging have lower failure rates than blind VCTE in the BMI >30 population, which is increasingly relevant as community elastography expands.

5. The Indeterminate FIB-4 Pathway in Practice

Most of the practical clinical decisions in primary care MAFLD management happen in the indeterminate FIB-4 zone. A workable in-practice pathway:

1. FIB-4 calculated at the point of routine bloods in any patient meeting screening criteria.
2. Result triaged into low / indeterminate / high zones — ideally automated within the practice software.
3. Indeterminate results trigger an elastography referral to a community elastography service or imaging centre with elastography capability.
4. Elastography result documented in the patient record, with the kPa value and the reliability indicator (IQR/M ratio).
5. Results <8 kPa: continue routine management. 8–12 kPa: consider specialist input. >12 kPa: refer.
6. Re-screen FIB-4 annually in the established MAFLD cohort. Re-scan with elastography in 12–24 months depending on baseline stiffness and clinical trajectory.

6. Treatment — What GPs Can Do

Lifestyle remains the foundation of MAFLD management. Weight loss of ≥7% reduces liver fat, ≥10% can reduce inflammation, and sustained metabolic improvement supports fibrosis stabilisation. These are not modest targets, but the GLP-1 and GIP-GLP-1 agonist landscape has changed what's achievable for many patients.

Pharmacotherapy options:

• GLP-1 agonists (semaglutide, liraglutide): meaningful weight loss and metabolic improvement; published improvements in liver biomarkers and steatosis. Not licensed specifically for MAFLD in Australia, but widely used for T2DM and weight management in MAFLD patients.
• Tirzepatide (Mounjaro): dual GIP/GLP-1 agonist with greater weight loss than semaglutide; emerging data on fibrosis response in MASH cohorts.
• Resmetirom (Rezdiffra): first MASH-specific therapy (FDA-approved March 2024, EMA-approved August 2025). TGA submission anticipated. Selective THR-β agonist; targets the liver pathology directly rather than working through metabolic improvement.
• Vitamin E: guideline-supported for biopsy-proven MASH in non-diabetic adults; modest effect size.

The clinical reality is that MAFLD treatment increasingly intersects with weight management, T2DM care, and cardiovascular risk reduction. GPs running structured chronic disease programmes are well-placed to deliver coordinated MAFLD care alongside existing workstreams.

7. When to Refer to Hepatology

Specialist referral is appropriate for: FIB-4 >2.67, elastography >12 kPa (or >9.5 with concerning clinical features), known or suspected cirrhosis, persistent ALT elevation >3x ULN without clear cause, suspected drug-induced or autoimmune component, or patient enrolment consideration for emerging MASH therapies.

Hepatology referral wait times across Australia vary significantly. Community-based elastography helps prioritise: patients with confirmed advanced fibrosis can be triaged urgently; patients with intermediate findings can be managed in primary care with planned re-assessment, reducing inappropriate specialist referrals.

8. HCC Surveillance Considerations

Hepatocellular carcinoma surveillance is recommended in cirrhotic patients from any cause — typically six-monthly liver ultrasound, with or without serum alpha-fetoprotein. MAFLD is increasingly important in this context because, uniquely, MAFLD-associated HCC can occur in non-cirrhotic livers (estimates: 20–30% of MAFLD-HCC cases occur without cirrhosis).

Current GESA guidance does not recommend HCC surveillance in non-cirrhotic MAFLD. The clinical implication is that risk stratification by fibrosis stage is critical: patients with confirmed F4/cirrhosis need surveillance; patients with F2–F3 need ongoing fibrosis monitoring; patients with F0–F1 can be managed within metabolic risk programs without specific HCC surveillance.

9. Documenting and Communicating

Clear documentation is what makes a screening programme sustainable. For each MAFLD patient: document the screening criterion that triggered assessment, the FIB-4 score and date, the elastography result (kPa, CAP/UAP, IQR ratio, date), the staging conclusion, and the management plan. This creates a defensible audit trail and supports continuity if the patient moves between clinicians.

Patient communication should be plain-language. A high FIB-4 is not a diagnosis — it's a probability score. A high kPa is not cirrhosis until imaging or specialist assessment confirms it. The point of communicating these results to patients is to motivate metabolic engagement, not to alarm.

10. Building the System in Your Practice

Practices that run effective MAFLD screening share four features: an automated FIB-4 calculation step in routine bloods triage, a clear elastography referral pathway with reliable local provider, a documented re-screening cadence built into recall workflows, and at least one clinician — often a nurse-led role — taking ownership of the programme's consistency.

The technology exists. The pathway is well-defined. The clinical impact of consistent MAFLD screening in primary care is significant: earlier identification of advanced fibrosis, fewer late-stage presentations, better-targeted specialist referrals, and a coherent framework for the growing cohort of patients on GLP-1 therapy or — when available — resmetirom.